Bifogade filer
NET ASSET VALUE – 30 September 2024
Kurs & Likviditet
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Flerie AB via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2024-10-04 08:00:00
On the 30 September 2024 Flerie AB's Net Asset Value (NAV) was SEK 4,262 million and NAV per share was SEK 54.59.
Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Prokarium | 42% | 475 | 6.09 | 11.1% |
| Xspray Pharma | 18% | 294 | 3.77 | 6.9% |
| Empros Pharma | 79% | 204 | 2.62 | 4.8% |
| KAHR Medical | 31% | 191 | 2.44 | 4.5% |
| Atrogi | 37% | 176 | 2.25 | 4.1% |
| Xintela | 56% | 165 | 2.11 | 3.9% |
| Lipum | 57% | 164 | 2.10 | 3.8% |
| Microbiotica | 11% | 135 | 1.73 | 3.2% |
| Geneos Therapeutics | 12% | 97 | 1.24 | 2.3% |
| Mendus | 24% | 96 | 1.23 | 2.3% |
| EpiEndo Pharmaceuticals | 9% | 56 | 0.72 | 1.3% |
| Toleranzia | 58% | 56 | 0.71 | 1.3% |
| Synerkine Pharma | 43% | 52 | 0.67 | 1.2% |
| AnaCardio | 19% | 52 | 0.66 | 1.2% |
| Egetis Therapeutics | 2% | 37 | 0.47 | 0.9% |
| Buzzard Pharmaceuticals | 14% | 29 | 0.37 | 0.7% |
| Sixera Pharma | 23% | 26 | 0.33 | 0.6% |
| Alder Therapeutics | 21% | 17 | 0.22 | 0.4% |
| Vitara Biomedical | 5% | 13 | 0.17 | 0.3% |
| Amarna Therapeutics | 58% | 11 | 0.15 | 0.3% |
| Strike Pharma | 16% | 9 | 0.11 | 0.2% |
| Total | 2,354 | 30.16 | 55.2% | |
| Commercial Growth | ||||
| NorthX Biologics | 92% | 189 | 2.42 | 4.4% |
| Symcel | 31% | 169 | 2.16 | 4.0% |
| Chromafora | 31% | 73 | 0.93 | 1.7% |
| Provell Pharmaceuticals | 72% | 69 | 0.88 | 1.6% |
| A3P Biomedical | 8% | 42 | 0.54 | 1.0% |
| Nanologica | 39% | 39 | 0.50 | 0.9% |
| Frontier Biosolutions | 2% | 19 | 0.24 | 0.4% |
| Bohus Biotech | 45% | 17 | 0.21 | 0.4% |
| Total | 616 | 7.89 | 14.5% | |
| Limited Partnerships, total | 92 | 1.18 | 2.2% | |
| Assets related to Portfolio companies | 289 | 3.70 | 6.8% | |
| Other assets and liabilities | 910 | 11.66 | 21.4% | |
| NAV | 4,262 | 54.59 | 100.0% | |
* indirect shares in Provell Pharmaceuticals